BR0214489A - Processo para a produção de um polipeptìdeo recombinante - Google Patents

Processo para a produção de um polipeptìdeo recombinante

Info

Publication number
BR0214489A
BR0214489A BR0214489-1A BR0214489A BR0214489A BR 0214489 A BR0214489 A BR 0214489A BR 0214489 A BR0214489 A BR 0214489A BR 0214489 A BR0214489 A BR 0214489A
Authority
BR
Brazil
Prior art keywords
nucleotide sequence
recombinant polypeptide
polynucleotide vector
host cell
sequence encoding
Prior art date
Application number
BR0214489-1A
Other languages
English (en)
Inventor
Kurt Schoergendorfer
Joerg Windisch
Renate Kunert
Florian Unterluggauger
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23304597&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0214489(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of BR0214489A publication Critical patent/BR0214489A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PROCESSO PARA A PRODUçãO DE UM POLIPEPTìDEO RECOMBINANTE". A presente invenção refere-se a um processo para a produção de uma célula hospedeira eucariótica transformada que expressa um polipeptídeo recombinante de interesse cujo processo compreende introduzir em uma célula hospedeira eucariótica: (a) um primeiro vetor de polinucleotídeo que compreende (i) uma primeira seq³ência de nucleotídeo que codifica um polipeptídeo recombinante de interesse e (ii) uma segunda seq³ência de nucleotídeo que codifica um marcador selecionável, cuja segunda seq³ência de nucleotídeo é amplificada quando a célula hospedeira está em contato com um agente de seleção e (b) um segundo vetor de polinucleotídeo que tem essencialmente a mesma seq³ência de nucleotídeo que o primeiro vetor de polinucleotídeo exceto que a segunda seq³ência de nucleotídeo é substituída por uma terceira seq³ência de nucleotídeo que codifica um marcador selecionável diferente, o primeiro vetor de polinucleotídeo e o segundo vetor de polinucleotídeo estando estavelmente integrados ao genoma da célula hospedeira.
BR0214489-1A 2001-11-28 2002-11-26 Processo para a produção de um polipeptìdeo recombinante BR0214489A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33386801P 2001-11-28 2001-11-28
PCT/EP2002/013297 WO2003046187A1 (en) 2001-11-28 2002-11-26 Method for producing a recombinant polypeptide

Publications (1)

Publication Number Publication Date
BR0214489A true BR0214489A (pt) 2004-10-19

Family

ID=23304597

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214489-1A BR0214489A (pt) 2001-11-28 2002-11-26 Processo para a produção de um polipeptìdeo recombinante

Country Status (19)

Country Link
US (1) US20050084969A1 (pt)
EP (1) EP1453966B1 (pt)
JP (1) JP4723185B2 (pt)
KR (1) KR20040063937A (pt)
CN (1) CN1596310A (pt)
AU (1) AU2002358047A1 (pt)
BR (1) BR0214489A (pt)
CA (1) CA2468832A1 (pt)
HR (1) HRP20040477A2 (pt)
HU (1) HUP0500059A2 (pt)
IL (1) IL161909A0 (pt)
MX (1) MXPA04005191A (pt)
NO (1) NO20042173L (pt)
NZ (1) NZ533133A (pt)
PL (1) PL370550A1 (pt)
RU (1) RU2004119814A (pt)
SI (1) SI1453966T1 (pt)
WO (1) WO2003046187A1 (pt)
ZA (1) ZA200403802B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033135A1 (en) * 2003-10-09 2005-04-14 Daewoong Co., Ltd. Process for purifying human thrombopoietin with high content of sialic acid
AR053416A1 (es) 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
TR201816045T4 (tr) 2007-10-12 2018-11-21 Hoffmann La Roche Birden fazla nükleik asitten protein ekspresyonu.
WO2012077128A1 (en) * 2010-12-07 2012-06-14 Intas Biopharmaceuticals Limited A novel cell line development process to produce recombinant proteins using twin vector expression system
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10066001B2 (en) 2013-03-15 2018-09-04 Apotex Inc. Enhanced liquid formulation stability of erythropoietin alpha through purification processing
JP6050289B2 (ja) * 2013-07-11 2016-12-21 Ｊｃｒファーマ株式会社 組換え蛋白質高発現細胞株の選択法
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2018162517A1 (en) 2017-03-10 2018-09-13 F. Hoffmann-La Roche Ag Method for producing multispecific antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
DE3624453A1 (de) * 1986-07-19 1988-01-28 Behringwerke Ag Verfahren zur herstellung von humanem antithrombin iii (atiii), dafuer geeignete vektoren und wirtszellen, so erhaltenes, biologisch aktives atiii und dieses enthaltende arzneimittel
EP0319206A3 (en) * 1987-11-30 1990-04-18 Berlex Laboratories, Inc. Gene amplification
IL118201A (en) * 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof

Also Published As

Publication number Publication date
RU2004119814A (ru) 2005-04-20
EP1453966A1 (en) 2004-09-08
KR20040063937A (ko) 2004-07-14
MXPA04005191A (es) 2005-04-29
CN1596310A (zh) 2005-03-16
AU2002358047A1 (en) 2003-06-10
US20050084969A1 (en) 2005-04-21
NO20042173L (no) 2004-08-11
JP4723185B2 (ja) 2011-07-13
HRP20040477A2 (en) 2005-06-30
ZA200403802B (en) 2005-07-01
PL370550A1 (en) 2005-05-30
EP1453966B1 (en) 2012-07-11
NZ533133A (en) 2006-02-24
SI1453966T1 (sl) 2012-11-30
HUP0500059A2 (hu) 2005-04-28
JP2005510242A (ja) 2005-04-21
CA2468832A1 (en) 2003-06-05
IL161909A0 (en) 2005-11-20
WO2003046187A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
BR0214489A (pt) Processo para a produção de um polipeptìdeo recombinante
BR0112979A (pt) Método de produzir domìnios de proteìna funcional
BR0112637A (pt) Sequências do vìrus do papiloma códon-otimizadas
BR0009884A (pt) Processos e composições para a inibição da função das sequências de polinucleotìdeos
Shimizu et al. Erroneous incorporation of oxidized DNA precursors by Y‐family DNA polymerases
AU2003264419A1 (en) Kdr peptides and vaccines containing the same
BR9808396A (pt) Processo para aumentar a deposição de um agente benéfico de uma composição em barra, e, barra
BR9815855A (pt) Genes e métodos para controle de nematóides em plantas
BRPI0500968A (pt) Emulsificador
FI934812A (fi) Stabiliserade entzymer
BR0214381A (pt) Composição de tinta pigmentada
BR0008181A (pt) Processo de preparação de cloro
Razin et al. Nuclear matrix attachment regions and topoisomerase II binding and reaction sites in the vicinity of a chicken DNA replication origin
BR9802403A (pt) Proteìna tendo atividade transglutaminase, dna, transformante, e, processo para produzir uma proteìna tendo uma atividade transglutaminase.
BR0309570A (pt) Fatores camp quiméricos para vacinação contra infecção por streptococcus
BRPI0411393A (pt) vetor de expressão da superfìcie celular do antìgeno do vìrus sars e microorganismos transformados pelo vetor
BR0112384A (pt) Recuperação do vìrus da cinomose partindo do cdna
BR9710911A (pt) Um processo para a formação de um perácido e uma composição compreendendo o perácido referido.
BR9911891A (pt) Proteases fundidas com variantes de inibidor de subtilisina de streptomyces
BR0005690A (pt) Produção recombinante de carotenóides, em particular, astaxantina
BR9912838A (pt) Tablete detergente
PT811071E (pt) Sequencias amolificadas derivadas do gene da desmina vectores que compreendem estas sequencias e suas utilizacoes para a producao de proteinas
BR0207709A (pt) Métodos de produção de um óxido de metal nióbio
BRPI0318594B8 (pt) proteína recombinante que possui um efeito anticâncer, seu gene de codificação, seu uso, medicamento para tratar cânceres, vetor de expressão e microrganismo transgênico
BR0102897A (pt) Processo para a preparação de organossililalquilpolissulfanos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E ,7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2064 DE 27/07/2010.